Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.41 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.41 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 5/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.33 |
| ▸ | HTR2C | P28335 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | HTR1D | P28221 | 1/20 | 0.33 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
| ▸ | HTR5A | P47898 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11484541 | 0.81 | ALDH1A1 (0.48) | ALDH1A1KDM4EHSD17B10TAS1R3TAS1R1 | |
| SCHEMBL14037359 | 0.81 | KDM4E (0.36) | ALDH1A1KDM4EMAPTMEP1BKMT2A | |
| SCHEMBL29309180 | 0.80 | ALDH1A1 (0.44) | ALDH1A1KDM4EHSD17B10TAS1R3TAS1R1 | |
| SCHEMBL24724553 | 0.77 | TUBB1 (0.35) | ALDH1A1KDM4EMAPTTSHRMEN1 | |
| SCHEMBL30570727 | 0.77 | TUBB1 (0.35) | ALDH1A1KDM4EMAPTTSHRMEN1 | |
| SCHEMBL13160390 | 0.77 | ALDH1A1 (0.45) | ALDH1A1KDM4EHSD17B10TAS1R3TAS1R1 | |
| SCHEMBL332311 | 0.76 | ALDH1A1 (0.39) | ALDH1A1KDM4EHSD17B10TAS1R3TAS1R1 | |
| SCHEMBL23967512 | 0.76 | TUBB1 (0.42) | ALDH1A1KDM4EMAPTMEN1KMT2A | |
| SCHEMBL14417429 | 0.76 | ALDH1A1 (0.44) | ALDH1A1KDM4EHSD17B10MAPTTSHR | |
| SCHEMBL14092120 | 0.74 | ALOX5AP (0.39) | ALDH1A1KDM4EMAPTTSHRMEP1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400520-A1 | 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-12-05 | — | — | US | disclosed |
| CN-108779076-B | 5-methyl-6-phenyl-4, 5-dihydro-2H-pyridazin-3-one derivatives | 大塚制药株式会社 | 2022-05-03 | — | — | CN | disclosed |
| US-20220024907-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2022-01-27 | — | — | US | disclosed |
| US-20220024907-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2022-01-27 | — | — | US | disclosed |
| US-11174251-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2021-11-16 | — | — | US | disclosed |
| US-11174251-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2021-11-16 | — | — | US | disclosed |
| EP-3423440-B9 | 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE FOR THE TREATMENT OF BRAIN TUMORS | OTSUKA PHARMA CO LTD (JP) | 2021-07-28 | — | — | EP | disclosed |
| US-20210171472-A1 | 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-06-10 | — | — | US | disclosed |
| EP-2598500-B1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS INC (US) | 2021-05-19 | — | — | EP | disclosed |
| EP-2598500-B1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS INC (US) | 2021-05-19 | — | — | EP | disclosed |
| US-20130090310-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2013-04-11 | — | — | US | disclosed |
| US-20130090310-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2013-04-11 | — | — | US | disclosed |
| US-8343954-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-8343954-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-8343954-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| WO-2012015972-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2012-02-02 | — | — | WO | disclosed |
| US-20120028923-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. | 2012-02-02 | — | — | US | disclosed |
| US-20120028923-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. | 2012-02-02 | — | — | US | disclosed |
| US-20120028923-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. | 2012-02-02 | — | — | US | disclosed |
| WO-2012015972-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2012-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171472-A1 | 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE | VHL, H1-5, PRMT5 | ALDH1A1 846/4885KDM4E 94/4885HSD17B10 1046/4885 |
| US-11174251-B2 | Compositions and methods for inhibition of the JAK pathway | JAK3, JAK2, JAK1 | ALDH1A1 3686/4885KDM4E 2724/4885HSD17B10 2285/4885 |
| US-20240400520-A1 | 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE | VHL, H1-5, PRMT5 | ALDH1A1 846/4885KDM4E 94/4885HSD17B10 1046/4885 |
| US-20120028923-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | ALDH1A1 3686/4885KDM4E 2724/4885HSD17B10 2285/4885 |
| US-20130090310-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | ALDH1A1 3686/4885KDM4E 2724/4885HSD17B10 2285/4885 |
| US-20220024907-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | ALDH1A1 3686/4885KDM4E 2724/4885HSD17B10 2285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.